期刊文献+

新辅助化疗在局部晚期乳腺癌治疗中的疗效评价 被引量:5

下载PDF
导出
摘要 目的评价新辅助化疗与传统的术后化疗在局部晚期乳腺癌治疗中的效果。方法 2003年10月至2005年10月天水市第一人民医院共收治60例局部晚期乳腺癌患者,30例患者行新辅助化疗,30例患者行术后化疗,对两组患者的手术切除率,5年局部复发率,5年远处转移率,3年及5年生存率,无瘤生存率,治疗前后CEA、CA-153水平等进行比较。结果新辅助化疗组5年局部复发率、5年远处转移率、手术切除率、3年生存率、5年生存率、5年无瘤生存率分别为10.0%、3.3%、96.7%、93.3/%、80.0%及66.6%;传统治疗组则分别为16.7%、10.0%、86.7%、76.7%、70.0%及46.7%,两组相比差异均有统计学意义(均P<0.05)。新辅助化疗组临床痊愈20例,好转4例,恶化6例,治愈率66.7%,好转率13.3%,总有效率80.0%;传统治疗组临床痊愈14例,好转7例,恶化9例,治愈率46.7%,好转率23.3%,总有效率70.0%;两组差异均有统计学意义(均P<0.05)。结论对局部晚期乳腺癌行新辅助化疗的疗效明显优于传统的术后化疗。
出处 《中国肿瘤外科杂志》 CAS 2012年第4期238-239,共2页 Chinese Journal of Surgical Oncology
  • 相关文献

参考文献3

二级参考文献26

  • 1[1]Hickman.Apoptosis induced by anticancer drugs [J].Cancer Metastasis Rev,1992,11: 121- 139. 被引量:1
  • 2[2]Meyn RE,Stephens LC,Hunter NR,et al.Induction of apoptosis in murine tumor by cyclophosphamide [J].Cancer Chemother Pharmacol,1994,33: 410- 414. 被引量:1
  • 3[3]Magno WB,Hirschfield L,Bhuiya T,et al.Correlation of proliferative index (PCNA reactivity and Ki- 67 reactivity) in primary breast carcinoma with hormore status,lymph node status and disease- free survival [J].Conn Med,1992,56(12): 667- 672. 被引量:1
  • 4[4]Tahan SR,Neuberg DS,Dieffenbach A,et al.Prediction of early relapse and shorten survival in patients with breast cancer by proliferation cell nuclear antigen score [J].Cancer,1993,71: 3552- 3559. 被引量:1
  • 5[5]Ellis PA,Smith IE,Detre S,et al.Reduced apoptosis and proliferation and increased Bcl- 2 in residual breast cancer following preoperative chemotherapy [J].Breast Cancer Res Treat,1998,48: 107- 116. 被引量:1
  • 6[6]Bhalla K,Harris WB.Molecular and biologic determinants of neoadjuvant chemotherapy of locoregional breast cancer [J].Semin Onco,1998,252(Suppl 3): 19- 24. 被引量:1
  • 7Shannon C,Smith I.Is there still a role for neoadjuvant therapy in breast cancer?[J].Crit Rev Oncol Hematol,2003,45(1):77-90. 被引量:1
  • 8Osborne CK.Adjuvant endocrine therapy[M] //Harris JR,Lippman ME,Osborne CK,et al.Diseases of the breast.3rd Ed.USA:Lippincott Williams & Wilkins,2004:865-891. 被引量:1
  • 9Mauriac L,Debled M,Durand M,et al.Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women[J].Ann Oncol,2002,13(2):193-198. 被引量:1
  • 10Horobin JM,Preece PE,Dewar JA,et al.Long-term follow-up of elderly patients with locoregional breast cancer treated with tamoxifen only[J].Br J Surg,1991,78(2):213-217. 被引量:1

共引文献18

同被引文献47

  • 1陈丽芹,王徐东,张子和.乳腺疾病的相关因素及防治措施[J].中国综合临床,2007,23(6):563-563. 被引量:17
  • 2孙燕,周际昌.临床肿瘤内科手册[M]人民卫生出版社,1987. 被引量:17
  • 3LU W L,LI H X,QIAN B Y,et al.The clinical characteristicsand prognosis of Chinese early stage breast cancer patients:aretro-spec-tive study[J].Breast J,2010,16(3):331-333. 被引量:1
  • 4FREI E 3RD.Clinical cancer research:an embattled species[J].Cancer,1982,50(10):1979-1992. 被引量:1
  • 5MIEOG J S,VAN DE VELDE C J.Neoadjuvant chemotherapy forearly breast cancer[J].Expert Opin Pharmacother,2009,10(9):1423-1434. 被引量:1
  • 6UNTC M,Konecn G E,Paepke S,et al.Current and future roleof neoadjuvant therapy for breast cancer[J].Breast,2014,23(5):526-537. 被引量:1
  • 7RAPOPORT B L,DEMETRIOU G S,MOODLEY S D,et al.When and how do I use neoadjuvant chemotherapy for breast canc-er [J].Curr Treat Options Oncol,2014,15(1):86-98. 被引量:1
  • 8GOLDHIRSCH A,WOOD W C,COATES A S,et al.Strategiesfor subtypes-dealing with the diversity of breast cancer:highlightsof the St.Gallen International Expert Consensus on the PrimaryTherapy of Early Breast Cancer 2011[J].Ann Oncol,2011,22(8):1736-1747. 被引量:1
  • 9MAMOUNES E P,WANG J,BRYANT J,et al.Patterns of loco-regional failure (LRF )in patients receiving neoadjuvant chemo-therapy (NC ):results from NSABP-18[J].Breast Cancer ResTreat,2003,82(Supple):17-23. 被引量:1
  • 10AL-AZHRI J,KORU-SENGUL T,MIAO F,et al.Predictors ofSurgery Types after Neoadjuvant Therapy for Advanced StageBreast Cancer:Analysis from Florida Population-Based CancerRegistry (1996-2009)[J].Breast Cancer (Auckl),2015,13(9):99-108. 被引量:1

引证文献5

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部